Severe thrombocytopenia after trastuzumab retreatment: a case report

BMC Research Notes

Luisa Fioretto¹  Catia Angiolini¹  Maria Simona Pino¹ 

[1] Department of Oncology, Oncology Unit, Azienda Sanitaria 10 Firenze, Florence, Italy

关键词: Thrombocytopenia;    Breast cancer;    Trastuzumab;   

Others  :  1141437
DOI  :  10.1186/1756-0500-6-400

 received in 2013-06-03, accepted in 2013-10-01,  发布年份 2013

【 摘 要 】

Background

Trastuzumab prolongs survival of human epidermal growth factor receptor 2-positive breast cancer patients in both the adjuvant and metastatic settings. Currently toxicity data are not available on retreatment of metastatic breast cancer patients who relapse after adjuvant trastuzumab. We report one patient with metastatic breast cancer who developed acute thrombocytopenia after trastuzumab infusion. This patient had trastuzumab treatment in the adjuvant setting.

Case presentation

A 70-year-old Caucasian woman received a diagnosis of metastatic breast cancer four years after her initial diagnosis of locally advanced, hormone receptors-positive, human epidermal growth factor receptor 2-positive breast cancer. Trastuzumab retreatment was planned. Less than 24 hours after trastuzumab infusion, the patient was admitted to the hospital for the appearance of diffuse petechial hemorrhages and ecchymosis. The patient was confirmed to have a severe trastuzumab-induced thrombocytopenia. A rapid and complete recovery was observed after high-dose intravenous corticosteroids and immunoglobulin. No trastuzumab retreatment was attempted.

Conclusion

Among the reported cases of trastuzumab-induced thrombocytopenia, this is the first report in the literature occurring in a patient retreated with trastuzumab after adjuvant therapy.

【 授权许可】

   
2013 Pino et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, Martino S, Mamounas EP, Kaufman PA, Wolmark N: Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011, 29:3366-3373.
• [2]Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulos G, Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R, Herceptin Adjuvant (HERA) Trial Study Team: Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011, 12:236-244.
• [3]Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J, Breast Cancer International Research Group: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011, 365:1273-1283.
• [4]Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, Utriainen T, Turpeenniemi-Hujanen T, Jyrkkiö S, Möykkynen K, Helle L, Ingalsuo S, Pajunen M, Huusko M, Salminen T, Auvinen P, Leinonen H, Leinonen M, Isola J, Kellokumpu-Lehtinen PL: Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 2009, 27:5685-5692.
• [5]Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
• [6]Baselga J, Carbonell X, Castañeda-Soto NJ, Clemens M, Green M, Harvey V, Morales S, Barton C, Ghahramani P: Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005, 23:2162-2171.
• [7]Hudis CA: Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007, 357:39-51.
• [8]Mantzourani M, Gogas H, Katsandris A, Meletis J: Severe thrombocytopenia related to trastuzumab infusion. Med Sci Monit 2011, 17:CS85-CS87.
• [9]Drudi F, Gianni L, Fantini M, Ravaioli A: Trastuzumab-related thrombocytopenia: always a self-limiting complication? Ann Oncol 2010, 21:668-669.
• [10]Jara Sánchez C, Olier Gárate C, García-Donas Jiménez J, Peñalver Párraga J: Drug-induced thrombocytopenia induced by trastuzumab: a special challenge in a curable disease. Ann Oncol 2009, 20:1607-1608.
• [11]Parikh O, Neave F, Palmieri C: Severe thrombocytopenia induced by a single infusion of trastuzumab. Clin Breast Cancer 2008, 8:285-286.
• [12]Cathomas R, Goldhirsch A, von Moos R: Drugs-induced immune thrombocytopenia. N Engl J Med 2007, 357:1870-1871.
• [13]George JN, Raskob GE, Shah SR, Rizvi MA, Hamilton SA, Osborne S, Vondracek T: Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 1998, 129:886-890.